SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (469)10/18/2005 11:57:22 PM
From: keokalani'nui  Read Replies (1) | Respond to of 590
 
Not a lot worth arguing about boys; leaks, whose is better, what will the fda want, is there a rational approval strategy, does erbi have an insurmountable lead, will amgn push a cogs advantage.

I'm an altruist here. We can all be pretty confident erbitux is not the best anti-egfr mab that has been or will be invented. All I really want to see is IMCL's patent get stuffed after another, any other, egfr mab is approved.



To: tuck who wrote (469)10/19/2005 1:53:09 AM
From: DewDiligence_on_SI  Respond to of 590
 
I think the safety edge of Pani vs Erb will be marginal. However, Pani’s bi-weekly (or even tri-weekly) dosing may be a significant edge in convenience vs Erb’s weekly dosing if/when Pani gains traction as a combo agent with chemo because the longer dosing interval better matches the typical chemo cycle.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News